Osteoarthritic Pain Drug Pipeline Analysis Report 2025

Approximately 240 million people worldwide have symptomatic osteoarthritis, including 18% of women and 10% of men aged 60 years and older. Osteoarthritic pain is considered a common symptom of osteoarthritis, with localized pain experienced in specific joints like the knees, hips, hands, or spine. Management of osteoarthritic pain requires a combination of treatments including lifestyle modifications, pharmacological options, and surgery in severe cases. The growing adoption of non-invasive treatments and the rising focus on biologics and novel therapeutics are likely to boost the growth of the drug pipeline in the near future.

Report Coverage

The Osteoarthritic Pain Drug Pipeline Insight Report by the publisher gives comprehensive insights into osteoarthritic pain therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for osteoarthritic pain. The osteoarthritic pain report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The osteoarthritic pain pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with osteoarthritic pain treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to osteoarthritic pain.

Osteoarthritic Pain Drug Pipeline Outlook

Osteoarthritic pain is a common symptom of osteoarthritis, which develops gradually and often varies in intensity depending on factors such as joint overuse, inflammation, and structural changes in the joint. The pain is usually confined to specific joints (knees, hips, hands, and spine), but may radiate to other areas. Osteoarthritic pain is commonly activity-induced with movements worsening the discomfort experienced by the patients.

Osteoarthritic pain therapeutics include analgesics (acetaminophen and NSAIDs), intra-articular injections (corticosteroids and hyaluronic acid), and topical agents, among others. Osteoarthritic pain emerging drugs like nerve growth factor (NGF) inhibitors target pain pathways with high specificity. Further, the increasing investment in research and development and the rising focus on disease-modifying drugs are anticipated to support the drug pipeline expansion in the coming years.

Osteoarthritic Pain Epidemiology

Osteoarthritis is a degenerative joint condition that causes symptoms of pain, stiffness, and swelling. In the United States, osteoarthritis affects 32.5 million adults, with the prevalence increasing significantly with age.

As per the Centers for Disease Control and Prevention (CDC), 1 out 5 adults in the United States are living with some type of arthritis, with osteoarthritis being the most the form of the disease.

Osteoarthritic Pain - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of osteoarthritic pain drug candidates based on several segmentations including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Biologics
• Gene Therapy
• Peptides
• Synthetic Hormones
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Osteoarthritic Pain - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials, with a substantial number of osteoarthritic pain drugs undergoing clinical development.

Osteoarthritic Pain - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under osteoarthritic pain pipeline analysis include small molecules, biologics, gene therapy, peptides, synthetic hormones, and others. The osteoarthritic pain report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for osteoarthritic Pain.

Osteoarthritic Pain Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the osteoarthritic pain drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed osteoarthritic pain therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. below is the list of a few players involved in osteoarthritic pain clinical trials:

• Kolon TissueGene, Inc.
• Grünenthal GmbH
• Jiangsu Aosaikang Pharmaceutical Co., Ltd.
• Saol Therapeutics Inc
• Curonix LLC

Osteoarthritic Pain - Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: RTX-GRT7039

Sponsored by Grünenthal GmbH, the objective of this randomized clinical trial is to investigate the efficacy and safety of the osteoarthritic pain drug candidate RTX-GRT7039 in patients experiencing moderate to severe pain associated with knee osteoarthritis. The study is under Phase III clinical development and has an estimated 930 participants.

Drug: SL-1002

Saol Therapeutics Inc. is conducting a Phase II study aimed at examining the efficacy and safety of the investigational injectable drug SL-1002 for osteoarthritic knee pain. The clinical trial has enrolled about 132 subjects and has a study period of up to 168 days.

Reasons To Buy This Report

The Osteoarthritic Pain Drug Report provides a strategic overview of the latest and future landscape of treatments for osteoarthritic pain. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within osteoarthritic pain pipeline insights.

Key Questions Answered in the Osteoarthritic Pain - Pipeline Insight Report

• What is the current landscape of osteoarthritic pain disease pipeline drugs?
• Which companies/institutions are developing osteoarthritic pain disease emerging drugs?
• How many phase II drugs are currently present in osteoarthritic pain disease pipeline drugs?
• Which company is leading the osteoarthritic pain disease pipeline development activities?
• What is the current osteoarthritic pain disease therapeutic assessment?
• What are the opportunities and challenges present in the osteoarthritic pain disease drug pipeline landscape?
• What is the efficacy and safety profile of osteoarthritic pain disease pipeline drugs?
• Which companies/institutions are involved in osteoarthritic pain disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in osteoarthritic pain disease?

This product will be delivered within 3-5 business days.